Research ArticleOriginal Article
Open Access

Survival and prognostic factors in women treated for epithelial ovarian cancer in western region of Saudi Arabia

Khalid H. Sait, Mohammad Z. Alam, Absarul Haque, Hesham K. Sait, Maram K. Sait and Nisreen M. Anfinan
Saudi Medical Journal February 2022, 43 (2) 146-155; DOI: https://doi.org/10.15537/smj.2022.43.2.20210626

References

  1. 1.↵
    1. Siegel R,
    2. Ma J,
    3. Zou Z,
    4. Jemal A.
    Cancer statistics, 2014. CA Cancer J Clin 2014;64:9–29.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Arbyn M,
    2. Weiderpass E,
    3. Bruni L,
    4. de Sanjosé S,
    5. Saraiya M,
    6. Ferlay J, et al.
    Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health 2020; 8: e191–e203.
    OpenUrl
  3. 3.↵
    1. Torre LA,
    2. Trabert B,
    3. DeSantis CE,
    4. Miller KD,
    5. Samimi G,
    6. Runowicz CD, et al.
    Ovarian cancer statistics, 2018. CA Cancer J Clin 2018; 68: 284–296.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Bray F,
    2. Ferlay J,
    3. Soerjomataram I,
    4. Siegel RL,
    5. Torre LA,
    6. Jemal A.
    Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Kurman RJ,
    2. Shih IM.
    The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010; 34: 433–443.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Lheureux S,
    2. Braunstein M,
    3. Oza AM.
    Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin 2019; 69: 280–304.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Bankhead CR,
    2. Kehoe ST,
    3. Austoker J.
    Symptoms associated with diagnosis of ovarian cancer: a systematic review. BJOG 2005; 112: 857–865.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Goff BA,
    2. Mandel LS,
    3. Melancon CH,
    4. Muntz HG.
    Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004; 291: 2705–2712.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Ozols RF.
    Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol 2006; 33: S3–S11.
    OpenUrlPubMedWeb of Science
  10. 10.↵
    1. Winter III WE,
    2. Maxwell GL,
    3. Tian C,
    4. Carlson JW,
    5. Ozols RF,
    6. Rose PG, et al.
    Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25: 3621–3627.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Wong KH,
    2. Mang OWK,
    3. Au KH,
    4. Law SCK.
    Incidence, mortality, and survival trends of ovarian cancer in Hong Kong, 1997 to 2006: a population-based study. Hong Kong Med J 2012; 18: 466–474.
    OpenUrl
  12. 12.↵
    1. Tewari KS,
    2. Java JJ,
    3. Eskander RN,
    4. Monk BJ,
    5. Burger RA.
    Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Annal Oncol 2016; 27: 114–121.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Baldwin LA,
    2. Huang B,
    3. Miller RW,
    4. Tucker T,
    5. Goodrich ST,
    6. Podzielinski I, et al.
    Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol 2012; 120: 612–618.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Markman M.
    Optimal management of recurrent ovarian cancer. Int J Gynecol Cancer 2009; 19: S40–S43.
    OpenUrlAbstract/FREE Full Text
  15. 15.
    1. Timmermans M,
    2. Sonke GS,
    3. van de Vijver KK,
    4. van der Aa MA,
    5. Kruitwagen RFPM.
    No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands. Eur J Cancer 2018; 88: 31–37.
    OpenUrlPubMed
  16. 16.↵
    1. Ercelep O,
    2. Ozcelik M,
    3. Gumus M.
    Association of lymphadenectomy and survival in epithelial ovarian cancer. Curr Probl Cancer 2019; 43: 151–159.
    OpenUrl
  17. 17.↵
    1. Duska LR,
    2. Chang Y,
    3. Flynn CE,
    4. Chen AH,
    5. Goodman A,
    6. Fuller AF, et al.
    Epithelial ovarian carcinoma in the reproductive age group. Cancer 1999; 85: 2623–2629.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Chang LC,
    2. Huang CF,
    3. Lai MS,
    4. Shen LJ,
    5. Wu FLL,
    6. Cheng WF.
    Prognostic factors in epithelial ovarian cancer: a population-based study. PLoS One 2018; 13: e0194993.
    OpenUrlPubMed
  19. 19.↵
    1. Akahira J-I,
    2. Yoshikawa H,
    3. Shimizu Y,
    4. Tsunematsu R,
    5. Hirakawa T,
    6. Kuramoto H, et al.
    Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol 2001; 81: 398–403.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Oliver KE,
    2. Brady WE,
    3. Birrer M,
    4. Gershenson DM,
    5. Fleming G,
    6. Copeland LJ, et al.
    An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: an NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol 2017; 147: 243–249.
    OpenUrl
  21. 21.↵
    1. Gates MA,
    2. Rosner BA,
    3. Hecht JL,
    4. Tworoger SS.
    Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol 2010; 171: 45–53.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.
    1. Melin A,
    2. Lundholm C,
    3. Malki N,
    4. Swahn M,
    5. Sparen P,
    6. Bergqvist A.
    Endometriosis as a prognostic factor for cancer survival. Int J Cancer 2011; 129: 948–955.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Karpathiou G,
    2. Chauleur C,
    3. Corsini T,
    4. Venet M,
    5. Habougit C,
    6. Honeyman F, et al.
    Seromucinous ovarian tumor A comparison with the rest of ovarian epithelial tumors. Ann Diagn Pathol 2017; 27: 28–33.
    OpenUrlPubMed
  24. 24.↵
    1. Chi DS,
    2. Liao JB,
    3. Leon LF,
    4. Venkatraman ES,
    5. Hensley ML,
    6. Bhaskaran D, et al.
    Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 2001; 82: 532–537.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.
    1. Wimberger P,
    2. Lehmann N,
    3. Kimmig R,
    4. Burges A,
    5. Meier W,
    6. du Bois A.
    Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVA. Gynecol Oncol 2007; 106: 69–74.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Chang SJ,
    2. Bristow RE,
    3. Ryu HS.
    Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann Surg Oncol 2012; 19: 4059–4067.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    1. Chang SJ,
    2. Hodeib M,
    3. Chang J,
    4. Bristow RE.
    Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol 2013; 130: 493–498.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Rajkumar S,
    2. Nath R,
    3. Lane G,
    4. Mehra G,
    5. Begum S,
    6. Sayasneh A.
    Advanced stage (IIIC/IV) endometrial cancer: role of cytoreduction and determinants of survival. Eur J Obstet Gynecol Reprod Biol 2019; 234: 26–31.
    OpenUrlPubMed
  29. 29.↵
    1. Tate S,
    2. Kato K,
    3. Nishikimi K,
    4. Matsuoka A,
    5. Shozu M.
    Survival and safety associated with aggressive surgery for stage III/IV epithelial ovarian cancer: a single institution observation study. Gynecol Oncol 2017; 147: 73–80.
    OpenUrl
  30. 30.↵
    1. Aletti GD,
    2. Long HJ,
    3. Podratz KC,
    4. Cliby WA.
    Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer? Gynecol Oncol 2007; 104: 212–216.
    OpenUrlCrossRefPubMed
  31. 31.
    1. Gadducci A,
    2. Cosio S,
    3. Zizioli V,
    4. Notaro S,
    5. Tana R,
    6. Panattoni A, et al.
    Patterns of recurrence and clinical outcome of patients with stage IIIC to stage IV epithelial ovarian cancer in complete response after primary debulking surgery plus chemotherapy or neoadjuvant chemotherapy followed by interval debulking surgery: An Italian multicenter retrospective study. Int J Gynecol Cancer 2017; 27: 28–36.
    OpenUrlAbstract/FREE Full Text
  32. 32.
    1. Larsen E,
    2. Blaakaer J.
    Epithelial ovarian cancer: does the time interval between primary surgery and postoperative chemotherapy have any prognostic importance? Acta Obstet Gynecol Scand 2009; 88: 373–377.
    OpenUrlPubMed
  33. 33.
    1. Xu F,
    2. Rimm AA,
    3. Fu P,
    4. Krishnamurthi SS,
    5. Cooper GS.
    The impact of delayed chemotherapy on its completion and survival outcomes in stage II colon cancer patients. PLoS ONE 2014; 9: e107993.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Nachiappan S,
    2. Askari A,
    3. Mamidanna R,
    4. Munasinghe A,
    5. Currie A,
    6. Stebbing J, et al.
    The impact of adjuvant chemotherapy timing on overall survival following colorectal cancer resection. Eur J Surg Oncol 2015; 41: 1636–1644.
    OpenUrl
  35. 35.↵
    1. Kim YW,
    2. Choi EH,
    3. Kim BR,
    4. Ko WA,
    5. Do YM,
    6. Kim IY.
    The impact of delayed commencement of adjuvant chemotherapy (eight or more weeks) on survival in stage II and III colon cancer: a national population-based cohort study. Oncotarget. 2017; 8: 80061.
    OpenUrl
  36. 36.↵
    1. Tsai YT,
    2. Lozanski G,
    3. Lehman A,
    4. Sass EJ,
    5. Hertlein E,
    6. Salunke SB, et al.
    BRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation. Leuk Res 2015; 39: 1270–1277.
    OpenUrl
  37. 37.↵
    1. Deng F,
    2. Xu X,
    3. Lv M,
    4. Ren B,
    5. Wang Y,
    6. Guo W, et al.
    Age is associated with prognosis in serous ovarian carcinoma. J Ovarian Res 2017; 10: 36.
    OpenUrlCrossRef
  38. 38.↵
    1. Bandera EV,
    2. Lee VS,
    3. Qin B,
    4. Rodriguez-Rodriguez L,
    5. Powell CB,
    6. Kushi LH.
    Impact of body mass index on ovarian cancer survival varies by stage. Br J cancer 2017; 117: 282–289.
    OpenUrl
  39. 39.↵
    1. Wang X,
    2. Li X,
    3. Su S,
    4. Liu M.
    Marital status and survival in epithelial ovarian cancer patients: a SEER-based study. Oncotarget 2017; 8: 89040.
    OpenUrlPubMed
  40. 40.↵
    1. Mahdi H,
    2. Kumar S,
    3. Munkarah AR,
    4. Abdalamir M,
    5. Doherty M,
    6. Swensen R.
    Prognostic impact of marital status on survival of women with epithelial ovarian cancer. Psychooncology 2013; 22: 83–88.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords